In the last micro-class of lipoprotein(a) master class, We interpreted the epidemiology and harm of calcific aortic valve stenosis (CAVS), the relationship between Lp(a) and CAVS, and the use of Lp(a) lowering therapy for CAVS management.
We are honored to invite a member of the Standing Committee of the Cardiovascular Medicine Branch of the Chinese Medical Doctor Association, the former vice president, and the current Chinese Gerontology and Professor Liu Meilin, deputy director of the Cardiovascular Branch of the Geriatrics Society and director of the Department of Geriatrics, Peking University First Hospital, introduced the mechanism of Lp(a) promoting cardiovascular disease (CVD) in detail. , the latest evidence on Lp(a) and CVD and the latest progress in Lp(a) research such as Lp(a) and CVD management.
Summary of key points: ღ Lp(a) is a lipoprotein independently synthesized by the liver, and its level Primarily determined by genetic factors and not interfered by gender, age, diet, or external physical factors, it is normallow-density lipoprotein cholesterol (LDL-C)levels The distribution differs, with Lp(a) levels being skewed in most populations, with most individuals (approximately 70%) having Lp(a) levels <30 mg/dl. (see the video below: 00:00-04:13)ღ Lp(a) Associated with an increased risk of atherosclerosis, inflammation, thrombosis, and aortic valve calcification. (see the video below: 04:14-8:21)
ღ Elevated Lp(a)levels are significantly associated with coronary heart disease and ischemic stroke,and poor prognosis in patients with myocardial infarction or ischemic stroke About.
(see the video below: 8:22-19:12)
ღ Elevated Lp(a) was significantly associated with heart failure with reduced ejection fraction (HFrEF); in addition, Lp(a) variability in patients with familial hypercholesterolemia was associated with major adverse cardiovascular events ( MACE) were significantly correlated.
(see the video below: 19:13-21:25)ღ Reducing Lp(a) is a CVD management strategy. Statins do not reduce Lp(a). Antisense oligonucleotides are the most potential new drugs to reduce Lp(a). (see the video below: 21:26-33:40)
Professional Profile
/p> •Director, Chief Physician, Professor, Doctoral Supervisor, Department of Geriatric Medicine, Peking University First Hospital. •Graduated from Beijing Medical College (now Peking University Medical School) in 1984. From June 1997 to July 1998, he studied coronary interventional treatment technology in Grantham Hospital, Hong Kong. From September 1999 to December 2002, he was engaged in the clinical and pathogenesis research of lipid metabolism, antioxidants and cardiovascular diseases at Uppsala University, Sweden. •Currently Member of the Standing Committee and Vice President of Cardiovascular Medicine Branch of Chinese Medical Doctor Association, Vice Chairman and Director General of Cardiovascular and Cerebrovascular Professional Committee of Chinese Gerontology and Geriatrics Society, China Member of the Standing Committee of the Cardiovascular Branch of the Medical Association, Vice Chairman of the Cardiovascular Professional Committee of the Beijing Medical Association, Vice President of the Cardiovascular Branch of the Beijing Medical Association, and Vice President of the Hypertension Branch of the Chinese Geriatrics Association. He is an expert member of the American College of Cardiology (FACC), an expert member of the European Society of Cardiology (FESC), a director of the Chinese Society of Gerontology and Geriatrics, and a director of the China Hypertension League. Deputy editor-in-chief of “Chinese Journal of Multiple Organs in the Elderly”, “Chinese Journal of Cardiovascular Diseases”, “Chinese Journal of Interventional Cardiology”, “Journal of Clinical Cardiovascular Diseases”, “Chinese Journal of Cardiovascular and Cerebrovascular Diseases in the Aged”, “Chinese Journal of Cardiovascular Diseases” ” and other editorial board. As the first or corresponding author, he has published more than 200 articles in domestic and foreign journals. Professor Liu Meilin
Review of Past Issues
☞ Lipoprotein (a) Master Class Phase 1｜Lipo-regulating A new vision of treatment, Professor Yuan Zuyi discusses the clinical significance of lipoprotein (a) in detail
☞ Lipoprotein (a) Master Class No. 2｜Professor Peng Daoquan: Lipoprotein (a) a) Pathophysiological mechanism of the causal relationship with CVD
☞ Lipoprotein (a) Master Class No. 3｜Professor Wu Pingsheng: The relationship between lipoprotein (a) and CVD Evidence-based evidence for causality
☞ Small lipoprotein(a) Master Class No. 4｜Professor Li Jianjun: Evidence of Lipoprotein(a) and CVD in Chinese population☞ Small lipoprotein(a) ) Master Class No. 5｜Professor Yuan Hui: Current Situation and Thinking of Clinical Testing of Lipoprotein(a)☞ Lipoprotein(a) Master Class No. 6｜< span>Professor Zhu Ye: Treatment of Elevated Lipoprotein(a)
☞ Lipoprotein(a) Master Class No.7｜Chen Zhenyue Professor: The latest progress of lipoprotein (a) and related guidelines/consensus interpretation
☞ Lipoprotein (a) small master class Issue 8｜Professor Sun Yihong: Interpretation of expert scientific advice on the relationship between lipoprotein(a) and cardiovascular risk and clinical management (Part 1)
☞Master Lipoprotein(a) Class No. 9｜Professor Guo Yuanlin: Interpretation of expert scientific advice on the relationship between lipoprotein(a) and cardiovascular risk and clinical management (Part 2)
☞< span>Lipoprotein (a) Master Class No. 10｜Professor Wu Naqiong: Starting from Lp(a), exploring new strategies for CAVS management